Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.66 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.66 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301105 | 1.00 | HTT (0.68) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6445345 | 1.00 | HTT (0.68) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL8340594 | 1.00 | HTT (0.68) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL19658435 | 0.95 | EPHX1 (0.63) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL600676 | 0.90 | PDPK1 (0.61) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL2466144 | 0.90 | PDPK1 (0.61) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1988494 | 0.90 | PDPK1 (0.61) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL8029932 | 0.90 | PDPK1 (0.61) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL11266196 | 0.88 | KMT2A (0.67) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1568062 | 0.85 | KMT2A (0.71) | HTTALDH1A1TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-02-27 | — | — | US | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20220119444-A1 | Inhibitor of Apoptosis Protein (IAP) Antagonists | Sanford Burnham Prebys Medical Discovery Institute | 2022-04-21 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| US-11111270-B2 | Inhibitor of apoptosis protein (IAP) antagonists | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-09-07 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-29 | — | — | US | disclosed |
| WO-2019178248-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-09-19 | — | — | WO | disclosed |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-02-14 | — | — | US | disclosed |
| US-8114991-B2 | Used for the control of a range of harmful weeds | BAYER CROPSCIENCE AG (DE) | 2012-02-14 | — | — | US | disclosed |
| EP-2305655-A2 | Amino-1,3,5-triazines N-substituted with chiral bicyclic radicals, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators. | Bayer CropScience AG (DE) | 2011-04-06 | — | — | EP | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-7592488-B2 | Method for preparing optically active amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-09-22 | — | — | US | disclosed |
| US-7592488-B2 | Method for preparing optically active amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-09-22 | — | — | US | disclosed |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-02-05 | — | — | US | disclosed |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2009-02-05 | — | — | US | disclosed |
| WO-2008144925-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008128121-A1 | SMAC MIMETIC DIMERS AND TRIMERS USEFUL AS ANTI-CANCER AGENTS | JOYANT PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20040157739-A1 | Amino-1,3,5-triazines N-substituted with chiral bicyclic radicals, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators | BAYER CROPSCIENCE AG (DE) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157739-A1 | Amino-1,3,5-triazines N-substituted with chiral bicyclic radicals, process for their preparation, compositions thereof, and their use as herbicides and plant growth regulators | CYP4Z1, IL4I1, BCAT1 | HTT 2360/4885ALDH1A1 797/4885TAS1R3 1645/4885 |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | HTT 4866/4885ALDH1A1 382/4885TAS1R3 943/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | HTT 4866/4885ALDH1A1 382/4885TAS1R3 943/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HTT 1689/4885ALDH1A1 1598/4885TAS1R3 3777/4885 |
| US-20190047990-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | HTT 1689/4885ALDH1A1 1598/4885TAS1R3 3777/4885 |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | HTT 3072/4885ALDH1A1 3348/4885TAS1R3 2831/4885 |
| US-20220119444-A1 | Inhibitor of Apoptosis Protein (IAP) Antagonists | API5, XIAP, BIRC5 | HTT 2134/4885ALDH1A1 4556/4885TAS1R3 3612/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HTT 1760/4885ALDH1A1 1601/4885TAS1R3 3806/4885 |
| US-11111270-B2 | Inhibitor of apoptosis protein (IAP) antagonists | API5, XIAP, BIRC5 | HTT 2134/4885ALDH1A1 4556/4885TAS1R3 3612/4885 |
| US-11912786-B2 | Inhibitor of apoptosis protein (IAP) antagonists | API5, XIAP, BIRC5 | HTT 2134/4885ALDH1A1 4556/4885TAS1R3 3612/4885 |
| US-10457669-B2 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HTT 1689/4885ALDH1A1 1598/4885TAS1R3 3777/4885 |
| US-20090035830-A1 | Method for Preparing Optically Active Amines | CEL, NAAA, LIPA | HTT 3582/4885ALDH1A1 482/4885TAS1R3 4346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.